Alembic Pharmaceuticals has informed that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024. With this, for all its USFDA facilities, EIRs are in place.
The above information is a part of company’s filings submitted to BSE.